Anti-Human CD5 (Clone UCHT-2) - DyLight® 550
| Code | Size | Price |
|---|
| LEI-C2052-50ug | 50 ug | £159.00 |
Quantity:
| LEI-C2052-100ug | 100 ug | £211.00 |
Quantity:
| LEI-C2052-200ug | 200 ug | £291.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG1
Antibody Clonality: Monoclonal
Antibody Clone: UCHT-2
Regulatory Status: RUO
Target Species: Human
Applications:
- Flow Cytometry
- Functional Study
Shipping:
2-8°C
Storage:
This DyLight® 550 conjugate is stable when stored at 2-8°C. Do not freeze.
Further Information
Antigen Distribution:
The CD5 antigen is present on approximately 70% of normal peripheral blood lymphocytes and >90% of all T-lymphocytes. T-lymphocytes in the thymus stain weakly while peripheral T-cells stain strongly. Monocytes, granulocytes and NK cells are not stained.1 Anti-CD5 also reacts with a distinct subset of normal B-lymphocytes, occasional cells in B-lymphocyte areas of spleen and lymph node, and most Ig+ B-chronic lymphoblastic leukemia (CLL) cells. The CD5 antigen has also been shown to be present on some lymphomas.
Concentration:
0.2 mg/ml
Conjugate/Tag/Label:
DyLight® 550
Format:
This DyLight® 550 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This DyLight® 550 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
Purified Recombinant Human CD5 (>98%)
Long Description:
Anti-Human CD5 can be used in research to study B-lymphocyte subsets or characterization of leukemias and lymphomas.
NCBI Gene:
921
Target:
CD5
References
1. Leukocyte Typing VI (1995) Oxford University Press
2. Leukocyte Typing III (1987) Oxford University Press
3. Beverly, P. C. L. et al. (1981) "Protides of the Biological Fluids," Vol. XXIX, Peeters, H. (ed.), Pergamon Press, Oxford, 653
Related Products
| Product Name | Product Code | Supplier | Anti-Human CD5 (Clone UCHT-2) - PerCP | LEI-C2059 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|